Part 1 of a 2-part webinar series, supported by AstraZeneca
During this webinar, the expert panel will discuss two recently published clinical trials (CALGB 140503 and JCOG 0802) that demonstrate equivalent survival for sublobar resection versus lobectomy for clinical stage IA cancer, peripheral <2cm. While both trials showed similar results, there are important differences in design, demographics, and patients’ outcomes. The presenters will debate the nuances of the trials and their potential applications in clinical practice.
Plan to attend Part 2 on Thursday, December 14, titled "Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC."
Robert E. Merritt, MD
The Ohio State University
Sandra L. Starnes, MD
University of Cincinnati Medical Center
Hari B. Keshava, MD
University of California, Irvine
Pro Sublobar Resection
Daniel L. Miller, MD
Medical College of Georgia
Con Sublobar Resection
Scott J. Swanson, MD
Brigham and Women's Hospital